CME/MOC Credit: Building Multidisciplinary Partnerships to Facilitate Genomic Testing and Master the Integration of EGFR-Targeted Therapy in Resectable Stage I-III NSCLC

Supporter Statement:
This CME/MOC activity is provided by PVI, PeerView Institute for Medical Education.This activity is supported by an independent educational grant from AstraZeneca.

Activity Description:
Disease recurrence rates in patients with stage IB-IIIA NSCLC are high and increase with disease stage, highlighting the urgency to improve patient outcomes. This improvement hinges on the optimal use of local therapies as well as aligning systemic therapies with disease biology, particularly actionable genomic alterations. Notably, EGFR mutations are common in all stages of NSCLC, including in earlier stages, rendering EGFR-targeted therapy a rational option for patients harboring these mutations. Adjuvant osimertinib has become the new standard of care for patients with stage I-III NSCLC exhibiting EGFR mutations. Furthermore, trials are underway exploring EGFR-targeted agents and other novel therapies in different settings in patients with resectable NSCLC. Consequently, there is an increasing need to conduct biomarker testing in earlier stages of NSCLC at the time of diagnosis to seamlessly incorporate targeted therapies into multimodal treatment plans for eligible patients.

In this PeerView MasterClass & Case Forum, a multidisciplinary panel of specialists in thoracic surgery and medical oncology will provide an essential overview of the latest clinical evidence supporting the use of adjuvant EGFR-directed and other targeted therapy options in stage I-III NSCLC and discuss the implications and applicability of the data in practice. Expert panelists will also use real-world case scenarios to dive deeper into the practicalities of biomarker testing and clinical integration of targeted therapies into treatment plans for eligible patients with resectable NSCLC. In addition, the panel will provide strategies for achieving better multidisciplinary partnerships in curative intent settings, with the ultimate goal of improving outcomes and quality of life for patients with resectable lung cancer.

To learn more and to register, visit PeerView.com/2024EGFR-Live.